Dasatinib

目录号:S1021 别名: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。

规格 价格 库存 购买数量  
RMB 1142.64 现货
RMB 1224.97 现货
RMB 3039.93 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献73篇:

客户使用该产品的13个实验数据:

  • Antitumor activity (A)and body weight (B) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model.

    Science, 2017, 9(414), doi: 10.1126/scitranslmed.aao1690. Dasatinib purchased from Selleck.

    Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述 Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。
靶点
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
体外研究

在抑制表达野生型Bcr-Abl或全部Bcr-Abl突变型(除了T315I)的Ba/F3增殖时,Dasatinib效果比Imatinib高很多。与Imatinib相比,Dasatinib呈2倍指数增长效力(约325倍)。Dasatinib有效抑制野生型Abl 激酶和全部突变型(除了T315I)。Dasatinib 直接靶向作用于野生型和突变型Abl激酶域,且抑制自磷酸化和底物磷酸化,这种作用存在浓度依赖性。Dasatinib作用于表达野生型 Bcr-Abl的细胞时,效果比Imatinib高325倍多。[1] TgE骨髓细胞菌落百分数从未处理孔的100% 降低到Dasatinib处理孔的4.12%。 有 Dasatinib存在时, WT 和TgE骨髓细胞形成的菌落百分数明显不同。LMP2A的表达可促进 B 淋巴细胞存活和增殖,而Dasatinib通过靶向作用于Lyn 和/或c-Abl 激酶可抑制以上存活和增殖。[2] Dasatinib 处理一系列甲状腺癌细胞,抑制Src信号, 降低生长速度,使细胞周期停滞,且诱导凋亡。使用剂量不断增加的 Dasatinib (0.019 μM 到 1.25 μM) 处理C643, TPC1, BCPAP, 和 SW1736 细胞3天,抑制50%细胞生长,然而抑制K1细胞系生长则需更高浓度Dasatinib。使用10 nM 或50 nM Dasatinib 处理BCPAP,SW1736 和 K1 细胞,导致G1期细胞提高9-22%,而S期细胞百分数则降低7-18%。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NYHJOWFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHHcYI4OiCq MnvySG1UVw>? M17OcmlEPTB;MD6wNFAxPyEQvF2= NXTXTFlVOTd7NU[wPFA>
K562 M{HHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\2cFczKGh? NFPyW4tFVVOR M13yW2lEPTB;MD6wNFEh|ryP M1HmT|E4QTV4MEiw
M07e Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHMO|IhcA>? NYHEXoE{TE2VTx?= NWfjTohvUUN3ME2wMlAxOTJizszN M2rUVlE4QTV4MEiw
ALL3 MYfDfZRwfG:6aXOgRZN{[Xl? MUSwMlHPxE1? M1r4RVczKGh? MlfYSG1UVw>? MnvzTWM2OD1yLkCwNFQh|ryP M3nhZ|E6QDh7NUSw
CML M3\zTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXKSVYzOCCvaX6= MVvEUXNQ NIe4eZhKSzVyPUCuNFAyKM7:TR?= M{ftPFE6OjF7MEG2
BA/F3 NEnnNGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PneVczKGh? NHvPdXVFVVOR NUfXOnlJUUN3ME22MlU5QSEQvF2= NUXwUZBOOjNyOEi2OFQ>
BA/F3 M3;kemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfqSI5mPzJiaB?= M4W4cmROW09? Moq4TY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDNN|UyXCCvdYThcpQhf2m2aDDJR|UxKG:oIECuNFAxQDQQvF2= MXWyN|A5QDZ2NB?=
BA/F3 M{LGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUi3NkBp NHjWXWhFVVOR NUPMfG9SUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKlcj3BZowhf2m2aDDJR|UxKG:oIECuNFA1Pc7:TR?= MoTZNlMxQDh4NES=
BA/F3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWi3NkBp NVHydnlYTE2VTx?= NIrCW3JKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJHQ{OTWLIH31eIFvfCC5aYToJGlEPTBib3[gNU44OTUQvF2= M3Xv[|I{ODh6NkS0
BA/F3 MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHXO|IhcA>? NWXKfWdKTE2VTx?= MX7JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>? NIe3WmUzOzNyMUewNy=>
BA/F3 NH7Sb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXwO|IhcA>? MljpSG1UVw>? NGD3dmZKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHMkW1T{BufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA{Os7:TR?= NVXkN29HOjN|MEG3NFM>
BA/F3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGW1bHc4OiCq NF6yU5NFVVOR NHr6[HFKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA2Oc7:TR?= Ml\5NlM{ODF5MEO=
BA/F3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWq3NkBp NXi3PVQ5TE2VTx?= MX3JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBSOjV{SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC4{txO MlHCNlM{ODF5MEO=
BA/F3 NEjCcpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD3Z|lCPzJiaB?= M1;4TGROW09? NF:zRVhKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAyO87:TR?= MlzkNlM{ODF5MEO=
BA/F3 M2jhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfTO|IhcA>? NV3tPIV2TE2VTx?= M3HwbGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViQlPSMWFDVCCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yMEG5{txO M13Rc|I{OzBzN{Cz
BA/F3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXe3NkBp NWjKN4Q4TE2VTx?= MVrJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? MWiyN|MxOTdyMx?=
BA/F3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPOOopjPzJiaB?= MVXEUXNQ M2DKe2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFR|MUXJJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMz62{txO MVWyN|MxOTdyMx?=
BA/F3 Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHkUZo4OiCq NFfDNIpFVVOR MoCwTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP Mmm4NlM{ODF5MEO=
T cell MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVr5SoRDPzJiaB?= NG\UVYtFVVOR NFq0S3RKdmirYnn0d{BidnSrIFPEN{0h[W6mIHHueIkhS0R{OD3pcoR2[2WmIGSgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iByLkCwN:69VQ>? MUKxO|E2PDVzMh?=
WiDr Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWS3NkBp MmfQSG1UVw>? NW\hUVd1UUN3ME2wMlA2OiEQvF2= NUm1RZJXOTV4MUW1NVI>
PC3 Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYC3NkBp NH[yfnFFVVOR MofITWM2OD1yLkCwPVQh|ryP NUTSfIdOOTV4MUW1NVI>
MDA-MB-231 NGLPW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M175clczKGh? NVHPe4FnTE2VTx?= NH\UXIVKSzVyPUCuNFEzKM7:TR?= MkG4NVU3OTV3MUK=
Hs578T NXXVUIh1S3m2b4TvfIlkKEG|c3H5 NY[0UXlxPzJiaB?= MXfEUXNQ Mlf5S2k2OD1yLkCzJO69VQ>? M{DvOVI1ODF3M{K3
HMEC NX24UWlMS3m2b4TvfIlkKEG|c3H5 NILO[Hg4OiCq NIfkXXhFVVOR NXLxNJRJT0l3ME2xMlgh|ryP MmXtNlQxOTV|Mke=
DU145 MkHhR5l1d3SxeHnjJGF{e2G7 NHfaT2o4OiCq Mo\tSG1UVw>? M2n1eWdKPTB;MD6xOkDPxE1? M3PleFI1ODF3M{K3
U251 Ml\sR5l1d3SxeHnjJGF{e2G7 NV25UG13PzJiaB?= MYPEUXNQ MmDNS2k2OD1{LkixJO69VQ>? NU\m[Jd5OjRyMUWzNlc>
NCI60 NET1fWFEgXSxdH;4bYMhSXO|YYm= MoHhO|IhcA>? MnG5SG1UVw>? MWnHTVUxRTVwNzFOwG0> MkPaNlQxOTV|Mke=
MALME-3M NHqwfFFEgXSxdH;4bYMhSXO|YYm= NHi2UnU4OiCq NHPwcoxFVVOR NV3Cc3lxT0l3ME22MlYyKM7:TR?= M3j5NlI1ODF3M{K3
KM12 MXLDfZRwfG:6aXOgRZN{[Xl? NGnTOY04OiCq NVv3bFRtTE2VTx?= M3fOU2dKPTB;Nz60OEDPxE1? MnPDNlQxOTV|Mke=
SW620 NV3vdIZUS3m2b4TvfIlkKEG|c3H5 M13ue|czKGh? MlP5SG1UVw>? M4\HT2dKPTB;OD60N{DPxE1? NIfVcHkzPDBzNUOyOy=>
RXF 393NL M334VGN6fG:2b4jpZ{BCe3OjeR?= NIjqfYM1KGSjeYO= MkOxSG1UVw>? MnHkTWM2OD1yLkCyNVch|ryP MWKyN|I2OzB5NB?=
LXFA 983L NVvC[YJ[S3m2b4TvfIlkKEG|c3H5 NWD1dGNmPCCmYYnz NIm2ZYxFVVOR M{T1[WlEPTB;MD6wOVY2KM7:TR?= MnHDNlMzPTNyN{S=
PRXF DU145 NYSyc3ZFS3m2b4TvfIlkKEG|c3H5 M4fsPFQh\GG7cx?= M4\lbWROW09? M3nWbmlEPTB;MD6wOlI{KM7:TR?= MlL6NlMzPTNyN{S=
PAXF 1657L MkHXR5l1d3SxeHnjJGF{e2G7 MY[0JIRigXN? MmPhSG1UVw>? MUPJR|UxRTBwMUKxJO69VQ>? MoD5NlMzPTNyN{S=
CXF 1103L NFvVV2NEgXSxdH;4bYMhSXO|YYm= MljQOEBl[Xm| MYrEUXNQ M1XTPWlEPTB;ND6zOkDPxE1? MVGyN|I2OzB5NB?=
GXF251L MYfDfZRwfG:6aXOgRZN{[Xl? MWO0JIRigXN? MYfEUXNQ MnuzTWM2OD1{LkK1JO69VQ>? MnLvNlMzPTNyN{S=
NCI-H23 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[3NkBp MUHEUXNQ NE\L[oZKSzVyPUKuNlch|ryP MVOyN|UzOTB{MB?=
HCT116 MmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvxSoQ4OiCq NEDETYFFVVOR M4XONGlEPTB;Mj6zJO69VQ>? MmPkNlM2OjFyMkC=
MCF7 MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[3NkBp M{LnO2ROW09? NUS1VWl2UUN3ME2yMlU4KM7:TR?= NFfBOWQzOzV{MUCyNC=>
NCI-H460 NHrjdJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWO3NkBp M3\KfmROW09? MYHJR|UxRThwOUmg{txO MXWyN|UzOTB{MB?=
DLD1 MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPGelI{PzJiaB?= MVzEUXNQ Mn3TTWM2OD12Lk[g{txO MXeyN|U3Pzl4MB?=
NCI-H661 NVLIeGw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXK3NkBp MmTaSG1UVw>? MXzJR|UxRTdwODFOwG0> MljmNlM2Pjd7NkC=
A549 NVPsXY02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3QO|IhcA>? NUDqeIxRTE2VTx?= NYnvV3hoUUN3ME24MlIh|ryP NVTXVlZiOjN3Nke5OlA>
U937 M1zueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnsdJE4OiCq MmO4SG1UVw>? NWXnU2l6UUN3ME2xNk4zKM7:TR?= MortNlM2Pjd7NkC=
HEK293 M1m0fmZ2dmO2aX;uJGF{e2G7 NELNZlAyOMLizszN MUjEUXNQ MmXOTY5lfWOnczDibY5lcW6pIHHm[olvcXS7IITvJIh2dWGwIH\1cIwudGWwZ4ToJGhqey22YXfn[YQhVXm2MTDrbY5ie2ViZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC5aYToJGlEPTBib3[gNE4xPjQQvF2= M3P5NVIzPzdyNkGw
HUVEC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7pfooxNjF3wrFOwG0> MXG3NkBp MkTPSG1UVw>? M4TaRmlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigZZQhOC5zNTD1US=> NWfubIRTOjJ6NUO5PVM>
HUVEC M1LNSmZ2dmO2aX;uJGF{e2G7 MmnmNVXDqM7:TR?= M4LCfFczKGh? NVP6TJd5TE2VTx?= NXLv[VhGUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1? Mlf2NlI5PTN7OUO=
Plasmodium falciparum NF2z[mtHfW6ldHnvckBCe3OjeR?= NWjG[4VKOTEEoN88US=> NWnQVIZHOTVibXnu MorsSG1UVw>? MXLJcohq[mm2czDQcIF{dW:maYXtJIZidGOrcHHyeY0heHKxbHnm[ZJifGmxbjDifUBqdmirYnn0bY5oKHSqZTDGeY5kfGmxbjDv[kBR\kOGUFuxJJBzd3SnaX6ge4l1cCCLQ{WwJI9nKDFwMUhOwG0> NIHXd4czPDV3MEOzNC=>
PC3 M3X6ZWZ2dmO2aX;uJGF{e2G7 NU\nU2x1OC5zIN88US=> M1XMNVUhcA>? MWXEUXNQ MX;Jcohq[mm2czDoeY1idiCSQ{OgZ4VtdCCjZHjld4lwdiCjdDCxNFAhdk1? MmnHNVk1PjJ7N{W=
DU145 MWjGeY5kfGmxbjDBd5NigQ>? MnrSNE4yKM7:TR?= MW[1JIg> NUPNd2FoTE2VTx?= M3S5b2lvcGmkaYTzJIh2dWGwIFTVNVQ2KGOnbHygZYRp\XOrb36gZZQhOTByIH7N MnHsNVk1PjJ7N{W=
PC3 M1;VZWtqdmG|ZTDBd5NigQ>? MWKwMlEh|ryP M{KyZVUhcA>? NUHh[XFiTE2VTx?= NX;zNm1iUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> MmXwNVk1PjJ7N{W=
DU145 MYLLbY5ie2ViQYPzZZk> NHXxdIkxNjFizszN NVPqbHRIPSCq NYnVfGViTE2VTx?= MVHJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2= NXX4Z5pkOTl2NkK5O|U>
PC3 NFjqfotMcW6jc3WgRZN{[Xl? NI\QSHcxNjFizszN NGXuZXc2KGh? NEHvT4dFVVOR MkfyTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJGZCUyC\NUe2M3k2PzdibHX2[Ywh[XRiMUCwJI5O M4DlT|E6PDZ{OUe1
DU145 MWjLbY5ie2ViQYPzZZk> M1[xOVAvOSEQvF2= M3H6d|UhcA>? MmXCSG1UVw>? Mlr3TY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCGVUG0OUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? NV\NWHE5OTl2NkK5O|U>
Huh7 NFWzXZNCdnSrdnnyZYwhSXO|YYm= M4PXflIvPSEQvF2= Ml[xOEBl[Xm| NULNZ5htTE2VTx?= MmLqTY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBpfW2jbjDIeYg4KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP NEjCWlYyPzN4ME[3Oi=>
C6/36 M2HTVmFvfGm4aYLhcEBCe3OjeR?= MVuyMlUh|ryP NWC0bHh5PCCmYYnz NUT6WXJKTE2VTx?= Ml7KTY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBie2mjbjD0bYdmeiCvb4PxeYl1dyCFNj:zOkBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[geolz[WxiZX72[YxweGVicILveIVqdiC5aYTobY4heGW{aX71Z4xm[XJicnXnbY9vKGG2IEKuOUB2VQ>? NFnBSlkyPzN4ME[3Oi=>
U937 NULq[pNOTnWwY4Tpc44hSXO|YYm= M{HOUFEh|ryP NVvZWm96OSCq M3vwW2ROW09? NWHR[4pFWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO= Mn;6NVc3QDRyOUm=
U937 NI\qOYlHfW6ldHnvckBCe3OjeR?= MkHINUDPxE1? NETOZooyKGh? M2CyeWROW09? NYTPcGRbWmWmdXPld{BNWFNvaX7keYNm\CCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? NEL1cFAyPzZ6NEC5PS=>
murine mast cell NFLwOm1HfW6ldHnvckBCe3OjeR?= MXuxJO69VQ>? NYTrXIVXOjRiaB?= M4Dwd2ROW09? NYTwRYRJUW6qaXLpeJMh[W62aXflck1qdmS3Y3XkJGlNPiC|ZXPy[ZRqd25iaX6gTYdGKHC{aX3l[EBud3W|ZTDtZZN1KGOnbHzzJIF1KDFidV2= NXTaZm5sOTd4OESwPVk>
BV-173 M4LpXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXUTWM2OD1yLkCwNFAxODFyOTFOwG0> NE[xfFZUSU6JRWK=
K-562 MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzqTWM2OD1yLkCwNFAxODJ4NjFOwG0> MWPTRW5ITVJ?
BL-70 NXf2VI43T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzaOVVDUUN3ME2wMlAxODByMEiyNkDPxE1? MmXPV2FPT0WU
EM-2 NF24R4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XxUWlEPTB;MD6wNFAxODFyODFOwG0> MnzqV2FPT0WU
LAMA-84 NVm2cZpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjGendrUUN3ME2wMlAxODByM{KxJO69VQ>? NFLyXZFUSU6JRWK=
MEG-01 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjZTWM2OD1yLkCwNFAxQThizszN NG\CeXdUSU6JRWK=
EoL-1-cell NHHEdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojOTWM2OD1yLkCwNFAyOzFizszN M4Duc3NCVkeHUh?=
CTV-1 MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHJeIZKSzVyPUCuNFAxODRyNDFOwG0> MlX6V2FPT0WU
TE-15 MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMEC1PFkh|ryP MmjKV2FPT0WU
NOS-1 NY\jc3BTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMEC2NVMh|ryP Mlv5V2FPT0WU
D-336MG NF71eWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrSfI9VUUN3ME2wMlAxPjNizszN MlTwV2FPT0WU
LB1047-RCC MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMEC5PFkh|ryP M1LTPXNCVkeHUh?=
LB996-RCC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\C[2lEPTB;MD6wNFk6OSEQvF2= MULTRW5ITVJ?
SW982 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\jO4lKSzVyPUCuNFEyOTVizszN MXjTRW5ITVJ?
TK10 M4\JUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnSc3lFUUN3ME2wMlAyOTd2IN88US=> Mn3jV2FPT0WU
A704 MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrremQ3UUN3ME2wMlAyPDlzIN88US=> MomwV2FPT0WU
TE-8 NXPNeXVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXhblR3UUN3ME2wMlAyPTd4IN88US=> M3vvUnNCVkeHUh?=
DOHH-2 M3qyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXwTWM2OD1yLkCxO|E6KM7:TR?= NVmyOVR5W0GQR1XS
HOP-62 NWfOcpk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwMEG4N|Qh|ryP NHHrcYNUSU6JRWK=
TE-12 NGLocFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z3e2lEPTB;MD6wNVg3OSEQvF2= M1HiTHNCVkeHUh?=
KGN MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv2c4J1UUN3ME2wMlAyQTR{IN88US=> MYHTRW5ITVJ?
NCI-H1648 NUfwNVNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHCZ284UUN3ME2wMlAzODFzIN88US=> MWnTRW5ITVJ?
OS-RC-2 MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXrWHBKSzVyPUCuNFIxOyEQvF2= NWL6TVFUW0GQR1XS
GB-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;XWWlKSzVyPUCuNFIyPTdizszN NGPtZlVUSU6JRWK=
RXF393 Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jpb2lEPTB;MD6wNlM2PyEQvF2= MXnTRW5ITVJ?
LC-2-ad MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnH[JBKSzVyPUCuNFI2QDZizszN NIe5bHlUSU6JRWK=
KS-1 NG\ISGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn6enFUUUN3ME2wMlAzPzNizszN NYTNWGhsW0GQR1XS
ETK-1 NX25TlBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjMOIVKSzVyPUCuNFI5OzJizszN Mmi4V2FPT0WU
SW954 MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLHTWM2OD1yLkCyPVI4KM7:TR?= MoD0V2FPT0WU
Becker M2\LU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwMEOwNFMh|ryP MUfTRW5ITVJ?
MZ1-PC NXLFclFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMEOxNVkh|ryP M2jTXHNCVkeHUh?=
ES6 NX;RdYlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwMEOxPVMh|ryP MmXBV2FPT0WU
KURAMOCHI MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrUTWM2OD1yLkCzOFg4KM7:TR?= MlrVV2FPT0WU
CGTH-W-1 NWTrOHVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHZTWM2OD1yLkCzOVQ5KM7:TR?= NF30e4FUSU6JRWK=
VA-ES-BJ M3vaXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMEO5NFIh|ryP NULZeIV4W0GQR1XS
LXF-289 MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3j2[2lEPTB;MD6wN|k2PiEQvF2= MoXmV2FPT0WU
MPP-89 M2nCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HnfGlEPTB;MD6wOFA1QSEQvF2= M4PtdHNCVkeHUh?=
SW872 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHLTWM2OD1yLkC0NVYyKM7:TR?= MlzMV2FPT0WU
SNB75 M2jaOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;kTWM2OD1yLkC0OFM2KM7:TR?= NYLTZ443W0GQR1XS
PSN1 NXXER3BmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHBO2JiUUN3ME2wMlA1PDd2IN88US=> NHf5fGhUSU6JRWK=
LB831-BLC M1HiRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi2OY1KSzVyPUCuNFQ3ODlizszN MnrPV2FPT0WU
MFH-ino M1fnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\SVmlEPTB;MD6wOFczPCEQvF2= NUPE[YpJW0GQR1XS
TGBC24TKB MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLqcG9kUUN3ME2wMlA1PzZzIN88US=> NWTiSI9wW0GQR1XS
A388 NXPpZoZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn2ZohKSzVyPUCuNFUxQTVizszN MXLTRW5ITVJ?
BB30-HNC NUnnbZhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HhOmlEPTB;MD6wOVQ{PyEQvF2= MnvoV2FPT0WU
GI-ME-N M2fSfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwME[xNVgh|ryP MUHTRW5ITVJ?
TGBC1TKB MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLZTXIyUUN3ME2wMlA3OTZ2IN88US=> M4Tl[3NCVkeHUh?=
TE-10 NETIZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jTe2lEPTB;MD6wOlM2PyEQvF2= NYLjUGlyW0GQR1XS
A498 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnVTWM2OD1yLkC3Nlg1KM7:TR?= MYPTRW5ITVJ?
TE-11 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfZTGY5UUN3ME2wMlA4QDV6IN88US=> MnPSV2FPT0WU
BB65-RCC NX7rSIxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInHOlVKSzVyPUCuNFgzOjdizszN NGPQ[VVUSU6JRWK=
C2BBe1 M3T2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHkZ3Y4UUN3ME2wMlA5OzB6IN88US=> M1Ln[nNCVkeHUh?=
NCI-H747 NXfsSZlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHtTWM2OD1yLkC4N|YzKM7:TR?= NYjCZ2JTW0GQR1XS
IST-MES1 NHTJOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XoN2lEPTB;MD6wPFU2OiEQvF2= Mkn4V2FPT0WU
KALS-1 NF7vcGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe5XXNGUUN3ME2wMlA6PDlizszN NV\Ofmo{W0GQR1XS
GCIY NITuOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvMRmZKSzVyPUCuNFk3PTZizszN MXLTRW5ITVJ?
RL95-2 M1TGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD3dXFKSzVyPUCuNVA{QCEQvF2= M1;qRXNCVkeHUh?=
TE-1 NWjQNJVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\ZTFlKSzVyPUCuNVA2PCEQvF2= M2\kbXNCVkeHUh?=
NCI-H1355 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnNfohKSzVyPUCuNVExOjhizszN NUHtU3J4W0GQR1XS
SW962 NUDac|lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUewUHpxUUN3ME2wMlEyOjl{IN88US=> NHLBdG1USU6JRWK=
KLE MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T4eWlEPTB;MD6xNVMyPyEQvF2= NWO1PHJOW0GQR1XS
MC116 NYLvW2JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMUG0NUDPxE1? Mmi1V2FPT0WU
NMC-G1 M3LCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz6ZWpHUUN3ME2wMlEyPjB4IN88US=> MkfuV2FPT0WU
KU812 NILJO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMUG4PFMh|ryP NIjFNoxUSU6JRWK=
COLO-829 NFXaZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwMUKyNVMh|ryP NX3oVZpnW0GQR1XS
NTERA-S-cl-D1 MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjsfolKSzVyPUCuNVIzQDNizszN NFm1VphUSU6JRWK=
IST-MEL1 M{DOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnsXoZQUUN3ME2wMlE{PDVizszN M4i5VnNCVkeHUh?=
MLMA MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:0b2lEPTB;MD6xOFA{OiEQvF2= NXPpO|NyW0GQR1XS
LS-123 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17pTWlEPTB;MD6xOFA3PCEQvF2= M{jZN3NCVkeHUh?=
LB2518-MEL MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwMUSxOlIh|ryP NVnlWWhSW0GQR1XS
NB69 MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMUS0N|Yh|ryP NYLWS5M6W0GQR1XS
8-MG-BA NIXHNIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwMUW0OVgh|ryP MXvTRW5ITVJ?
K5 M1PT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\sco5RUUN3ME2wMlE3PDh7IN88US=> MnrJV2FPT0WU
KINGS-1 NEnQN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDicVFKSzVyPUCuNVY3PjZizszN NGTYZWtUSU6JRWK=
SF268 M{XVN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7FTWM2OD1yLkG3OFA1KM7:TR?= MoG4V2FPT0WU
PF-382 MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2T0SmlEPTB;MD6xO|Y4QCEQvF2= M{LmZnNCVkeHUh?=
SH-4 M2m3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrzR2N4UUN3ME2wMlE5PDF|IN88US=> MkTWV2FPT0WU
NALM-6 NUPSS4lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fqU2lEPTB;MD6xPVI6PSEQvF2= MYDTRW5ITVJ?
CP66-MEL NHnGdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMUm1N|Eh|ryP NFy0fIxUSU6JRWK=
697 NGHVRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvHbohKSzVyPUCuNVk6QDdizszN M2DuVXNCVkeHUh?=
CP67-MEL MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMkC0PFgh|ryP NXrXbFNDW0GQR1XS
DSH1 NWf0OWU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P3VWlEPTB;MD6yOFAxOSEQvF2= NELpR4RUSU6JRWK=
HCE-4 NVT1XHhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTaTWM2OD1yLkK2OFM6KM7:TR?= NV7LUlZSW0GQR1XS
MZ2-MEL NWPXfWN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMki1N|ch|ryP NHO2ZlhUSU6JRWK=
BL-41 M1;UZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XsUWlEPTB;MD6yPVEzOyEQvF2= M2TBW3NCVkeHUh?=
HUTU-80 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHNemdKSzVyPUCuN|E1OiEQvF2= NXO3blNUW0GQR1XS
LOXIMVI NUi1VJM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPUTWM2OD1yLkOxOVA{KM7:TR?= MWfTRW5ITVJ?
no-10 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwM{G5N|Eh|ryP MXPTRW5ITVJ?
KARPAS-422 NY\TS2xuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwM{O5PVch|ryP M4f3[HNCVkeHUh?=
SW684 MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETSfGxKSzVyPUCuN|Q6QCEQvF2= NFXrOWVUSU6JRWK=
SF126 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnYTWM2OD1yLkO1OFEh|ryP MmXzV2FPT0WU
D-263MG MlrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;OTWM2OD1yLkO2NlI1KM7:TR?= NVPmUGdoW0GQR1XS
OVCAR-4 MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjxOWRKSzVyPUCuN|c1OzNizszN MUjTRW5ITVJ?
BB49-HNC NGjp[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nib2lEPTB;MD6zPFU6QSEQvF2= M{LSb3NCVkeHUh?=
ONS-76 NXfRTFdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1K2[mlEPTB;MD60Nlk2OSEQvF2= MkTHV2FPT0WU
MZ7-mel NX:3dGhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ntZmlEPTB;MD60O|kyOSEQvF2= NXXTc|dTW0GQR1XS
RCC10RGB MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPTTWM2OD1yLkS5NVEh|ryP NHPTNGlUSU6JRWK=
BOKU NU\LbWlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwNEmxN|Mh|ryP NXrhWI5vW0GQR1XS
no-11 NHXVWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm5WHlyUUN3ME2wMlUxOjJ6IN88US=> NID0RVJUSU6JRWK=
IST-SL2 NHrJ[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknnTWM2OD1yLkWwN|AzKM7:TR?= MlK3V2FPT0WU
RKO MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXWTWM2OD1yLkWyPVY3KM7:TR?= Ml\5V2FPT0WU
HT-144 NUjROoN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXMU2ZkUUN3ME2wMlU{PjB7IN88US=> NF;TfGZUSU6JRWK=
NCI-H446 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2i2[2lEPTB;MD62Nlc3KM7:TR?= Mm\NV2FPT0WU
QIMR-WIL NU\aPYxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTPTWM2OD1yLkewOlI6KM7:TR?= MkLuV2FPT0WU
MHH-PREB-1 NWW0Xo41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLzdnVRUUN3ME2wMlc1PDZ7IN88US=> M{POc3NCVkeHUh?=
EW-16 NVTHPFhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwN{[xO|gh|ryP NVjCcXhOW0GQR1XS
EW-24 M2T5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnyTWM2OD1yLke4NVY2KM7:TR?= MXPTRW5ITVJ?
LB373-MEL-D NVywV4c6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TYWmlEPTB;MD64NlUxQCEQvF2= MVjTRW5ITVJ?
TE-9 MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwOEe1N|Ih|ryP MYXTRW5ITVJ?
A3-KAW M1L4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvsfpQyUUN3ME2wMlk5PDV{IN88US=> Mn;yV2FPT0WU
A101D M1;xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rvVmlEPTB;MT6wN|A1OyEQvF2= M4XsZXNCVkeHUh?=
OCUB-M MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL3d4ZKSzVyPUGuNFQ1OTJizszN MnTTV2FPT0WU
ES4 M2DCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{iyZmlEPTB;MT6wOVE1PSEQvF2= NEfFemVUSU6JRWK=
TE-6 NVzB[4ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHnUWRKSzVyPUGuNlEzOjZizszN NV\2[pcxW0GQR1XS
D-502MG M2TLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGKxXoVKSzVyPUGuNlM{PzZizszN NYP2UXN[W0GQR1XS
KNS-42 NI\CcYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjPV4lJUUN3ME2xMlI1PDF{IN88US=> NEjLPZBUSU6JRWK=
SNU-C2B MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D5eWlEPTB;MT6zNFU5QSEQvF2= MWPTRW5ITVJ?
NCI-H1838 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\qOmlEPTB;MT6zNFc{OyEQvF2= NU\URWEyW0GQR1XS
NKM-1 M3;ZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFyxcVBKSzVyPUGuN|A5PTlizszN MlrZV2FPT0WU
GI-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzuNGdRUUN3ME2xMlM3OjJizszN NWrwdmpCW0GQR1XS
NB5 M1zYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTFwM{m4Nlch|ryP M3HEbHNCVkeHUh?=
CAS-1 NFXmfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjhdplKSzVyPUGuOFA6QTJizszN M1jHRXNCVkeHUh?=
HCE-T MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LSSGlEPTB;MT61OlcyPCEQvF2= M3\Y[HNCVkeHUh?=
SBC-1 NF30PYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPiTWM2OD1zLkW3PVg1KM7:TR?= NFHDcnNUSU6JRWK=
JiyoyeP-2003 MlfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwN{O0OlYh|ryP NU\4WW5sW0GQR1XS
TE-5 M{CwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjlRZpKSzVyPUGuO|kyOzlizszN Ml\3V2FPT0WU
CAN M2HCTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTFwOEKyOVIh|ryP MULTRW5ITVJ?
SK-UT-1 NWLBOGk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljJTWM2OD1{LkG2Olk{KM7:TR?= MkDTV2FPT0WU
JVM-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfvWIRKSzVyPUKuN|YzQDRizszN NFzDeolUSU6JRWK=
LB771-HNC M33vZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC1fFhRUUN3ME2yMlU4PTVzIN88US=> MU\TRW5ITVJ?
NCCIT MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXDTWM2OD1{Lki2OlE3KM7:TR?= MY\TRW5ITVJ?
NCI-H2126 MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jUdGlEPTB;Mj64O|U2OiEQvF2= MVrTRW5ITVJ?
Calu-6 MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLCS2JKSzVyPUOuNFU4PDFizszN Mny2V2FPT0WU
SK-LMS-1 NEX6VZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTNwMUG4PFYh|ryP NWfKeZl5W0GQR1XS
ARH-77 M2fI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf0bYFJUUN3ME2zMlQ3QTF3IN88US=> M3fYXXNCVkeHUh?=
NB17 MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\2U2lEPTB;Mz62N|g1PyEQvF2= MnjDV2FPT0WU
A253 MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXMTWM2OD1|LkezNlQ3KM7:TR?= M1XXe3NCVkeHUh?=
OPM-2 NWXDeXZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTRwMke2PFUh|ryP MV\TRW5ITVJ?
MV-4-11 NXjaVYVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3ITWM2OD12LkO2OFU1KM7:TR?= MnO3V2FPT0WU
SR M3rOSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vUdGlEPTB;ND60PVk2PCEQvF2= NFjLc2xUSU6JRWK=
KG-1 M1LPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nENWlEPTB;ND62NFg1PSEQvF2= MYPTRW5ITVJ?
OCI-AML2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHJTWM2OD13Lki2NVU1KM7:TR?= NIPidZZUSU6JRWK=
D-247MG NUPsUlc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHpUYtPUUN3ME22MlEzPTF7IN88US=> NWHheZJmW0GQR1XS
DJM-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTZwNEi1OVgh|ryP NGP6XVJUSU6JRWK=
RPMI-6666 M1vCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r3V2lEPTB;Nz6yO|A3PyEQvF2= Mmi4V2FPT0WU
KARPAS-45 MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\3VGlEPTB;Nz61NVY4OSEQvF2= M3zHV3NCVkeHUh?=
LP-1 Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTdwNUS3PFIh|ryP MoX2V2FPT0WU
RS4-11 MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITDbZNKSzVyPUeuOlU4QDdizszN NV7hZXBNW0GQR1XS
DU-4475 Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L3XmlEPTB;OD6yNVY2OiEQvF2= M{HR[nNCVkeHUh?=
MONO-MAC-6 M2DtOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRThwMkewOlYh|ryP NEPSfHVUSU6JRWK=
NCI-SNU-16 MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRThwNU[xNlgh|ryP NH7He|RUSU6JRWK=
SJSA-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\jdmlEPTB;OD63NlgxPSEQvF2= NHy2OY5USU6JRWK=
MMAC-SF M2ToZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTubJFNUUN3ME24Mlc6OzB5IN88US=> MYrTRW5ITVJ?
SK-NEP-1 NV\NbJloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTNZohxUUN3ME24Mlg6OTV3IN88US=> NGP3eplUSU6JRWK=
J-RT3-T3-5 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHZUIRKSzVyPUiuPVY2OjlizszN NHPsR29USU6JRWK=
SKM-1 MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmS1TWM2OD17LkCxO|M1KM7:TR?= NF\ySWdUSU6JRWK=
LB2241-RCC MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH6RmFTUUN3ME25MlAzODF{IN88US=> MULTRW5ITVJ?
SIG-M5 MkfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTlwMEK0PVMh|ryP NEfqeFRUSU6JRWK=
EVSA-T MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mom0TWM2OD17LkK3O|k{KM7:TR?= M{Hk[HNCVkeHUh?=
GT3TKB NV\sTmRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjnfYlKSzVyPUmuN|U2PDZizszN MX7TRW5ITVJ?
NB6 NYnWeWs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HIWGlEPTB;OT65NlI2QSEQvF2= M2r4PHNCVkeHUh?=
EHEB M2\UdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjMTWM2OD1zMD6wOlU3KM7:TR?= MnL0V2FPT0WU
HEL MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfLR4xHUUN3ME2xNE41Pzd4IN88US=> NWfpZZVZW0GQR1XS
ALL-PO NED6VZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTFyLke5N|gh|ryP Mn73V2FPT0WU
TGW NIDodW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\jOlN6UUN3ME2xNU4zQDJ6IN88US=> MlLyV2FPT0WU
BC-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEezeG9KSzVyPUGyMlEyOzhizszN NVLNbmFHW0GQR1XS
IA-LM MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTF{LkS0OFUh|ryP NWnaTFRnW0GQR1XS
UACC-257 MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofETWM2OD1zMj65NVk5KM7:TR?= Moe0V2FPT0WU
KP-N-YS NG\SRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfCU49PUUN3ME2xNk46Ojh|IN88US=> NHf0W|JUSU6JRWK=
Raji NHmyXI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzwTWM2OD1zMz63OFk4KM7:TR?= MWLTRW5ITVJ?
SF539 M4XhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTF|Lki1OVch|ryP MXPTRW5ITVJ?
DMS-153 NXjKXWxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXrR2NKSzVyPUG0MlAxOjhizszN NELWZ|VUSU6JRWK=
L-540 NG\IdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTF3LkC2O|Ih|ryP NF3ub3BUSU6JRWK=
MN-60 NEXI[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XZeGlEPTB;MUWuNVk4QSEQvF2= M4mzdnNCVkeHUh?=
RPMI-8866 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7LPJdKSzVyPUG3MlQ1PTRizszN NGTjR|ZUSU6JRWK=
NCI-H510A MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHzTWM2OD1zOT6zPVc{KM7:TR?= MWTTRW5ITVJ?
NB13 M4C1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF7LkS4O|ch|ryP MWrTRW5ITVJ?
HAL-01 Ml\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzRXlBKSzVyPUG5Mlc2PDNizszN NXXUeI1JW0GQR1XS
NCI-H720 NH7BU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjjeGxKSzVyPUKwMlI4OzNizszN NU\xS4pSW0GQR1XS
REH MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\BTWM2OD1{MD62N|U4KM7:TR?= M4XqNXNCVkeHUh?=
KNS-81-FD MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDlOmZLUUN3ME2yN{4yPDZizszN M4HBUHNCVkeHUh?=
HC-1 M1z4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfMdmFmUUN3ME2yOE42PTVzIN88US=> NHXOTmpUSU6JRWK=
NCI-H2141 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJ2Lke3OVQh|ryP NGXlb25USU6JRWK=
MOLT-4 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrGTWM2OD1{Nj62O|U{KM7:TR?= MoSyV2FPT0WU
OMC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\xe3pKSzVyPUK3MlE1OjJizszN MkCzV2FPT0WU
LC-1F NUHHSWFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPWW4hKSzVyPUK3MlMzPDVizszN NH;IXVNUSU6JRWK=
NCI-H1304 MmrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\NVW9yUUN3ME2yPE4yPjJ6IN88US=> MXrTRW5ITVJ?
BC-1 NUK5OZg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTJ6Lk[1NUDPxE1? MojPV2FPT0WU
NCI-H64 M2XO[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELqTFJKSzVyPUK5MlYzPTNizszN M17Y[HNCVkeHUh?=
MOLT-16 M1ztT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M36zUWlEPTB;MkmuOlI6OiEQvF2= NHm4UllUSU6JRWK=
U-87-MG NWXRN5d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTNyLke2OkDPxE1? M4jGRnNCVkeHUh?=
GAK NYnVVJRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlj2TWM2OD1|MT6yOlg3KM7:TR?= MonxV2FPT0WU
ES8 NXz6Z|l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkiwTWM2OD1|Mj6xNlUzKM7:TR?= MVXTRW5ITVJ?
HCC1599 NUPoPYFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTN{LkOzNlUh|ryP NXTTcY15W0GQR1XS
EB-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HncWlEPTB;M{SuN|EyPyEQvF2= NX;BfVJqW0GQR1XS
HCC1187 NFTpeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFuwe2JKSzVyPUO1MlgxPTJizszN NUOzd2JiW0GQR1XS
SK-PN-DW MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkC0TWM2OD1|Nj6xPVQ{KM7:TR?= MknKV2FPT0WU
JVM-3 NY\iTpZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr6V2dKSzVyPUO3MlI{OzhizszN NXHIc25kW0GQR1XS
HCC2157 M3LuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1foOWlEPTB;M{euPVk1PiEQvF2= MVvTRW5ITVJ?
A4-Fuk NYr4b2hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTN6LkGwNFkh|ryP MonnV2FPT0WU
COR-L279 MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLvTWM2OD12MD6yPFUyKM7:TR?= MnTKV2FPT0WU
DEL NYTlOYxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXTTWM2OD12MT65NFg3KM7:TR?= NYKzWXJ[W0GQR1XS
NCI-H1395 NWDwcpNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nzV2lEPTB;NEKuNFE3OyEQvF2= MmfSV2FPT0WU
MHH-NB-11 NX7Z[mV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTR|LkC4NVgh|ryP M{jKRnNCVkeHUh?=
NCI-H2107 M3joXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly1TWM2OD12Mz60PFQ3KM7:TR?= NXmydZI5W0GQR1XS
NEC8 NIDv[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3DOGpMUUN3ME20OE4{OzZizszN MmPNV2FPT0WU
COLO-684 MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTR4LkKyOVgh|ryP NV32SIJ1W0GQR1XS
LS-411N M{PtUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTR6LkS3OFgh|ryP MmLsV2FPT0WU

... Click to View More Cell Line Experimental Data

体内研究 Dasatinib 作用于LMP2A/MYC 双转基因小鼠,可逆转脾肿大。Dasatinib 作用于TgE小鼠 抑制表达LMP2A 的骨髓B 细胞形成的菌落,且使脾脏变小。使用Dasatinib处理Tg6/λ-MYC 小鼠,与对照组相比,脾脏质量明显降低。Dasatinib 作用于LMP2A/MYC 双转基因小鼠,抑制淋巴结肿大。Dasatinib作用于嫁接LMP2A/MYC双转基因小鼠肿瘤细胞的Rag1KO小鼠,可逆转脾肿大。Dasatinib 作用于表达LMP2A的B 淋巴细胞瘤,抑制Lyn磷酸化。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

激酶自磷酸化分析:

使用野生型和突变型谷胱甘肽S-转移酶(GST)-Abl融合蛋白 (c-Abl氨基酸220-498位) 进行激酶实验。从谷胱甘肽琼脂糖珠中释放GST-Abl融合蛋白,ATP浓度为5 μM。在用于激酶自磷酸化和体外肽底物磷酸化实验前, 用LAR酪氨酸磷酸酶处理GST-Abl 激酶域融合蛋白。在 30oC下温育1小时后,加入1 mM 钒酸钠,激活LAR磷酸酶。进行免疫印迹分析,比较未处理的GST-Abl激酶和去磷酸化的GST-Abl激酶,使用磷酸化的特点抗体4G10来 确认酪氨酸残基完全去磷酸化(>95%),使用c-Abl抗体 CST 2862 来确认GST-Abl激酶的平衡负载。实验测定IC50值时所用Dasatinib浓度为0 nM到32 nM。Dasatinib作用于突变型T315I时浓度达到 1,000 nM。在体外肽底物磷酸化实验中使用相同抑制剂浓度。作用于GST-Src激酶和 GST-Lyn激酶的三种抑制剂的浓度范围相同。
细胞实验: [1]
+ 展开
  • Cell lines: Ba/F3细胞系
  • Concentrations: 0 nM-32 nM
  • Incubation Time: 72小时
  • Method: Ba/F3 细胞系重复培养三份,然后与浓度逐渐升高的 Dasatinib 温育72小时。通过MTS活性实验测定细胞增殖。IC50值和IC90值取自三组独立实验的平均值。Dasatinib作用的IC50值和IC90值为0 nM 到32 nM 。Dasatinib 作用于突变型T315I时所需浓度达到200 nM。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: EμLMP2A(TgE 和Tg6品种),MYC (λ-MYC), 和LMP2A/λ-MYC双转基因小鼠(Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 488.01
化学式

C22H26ClN7O2S

CAS号 302962-49-8
稳定性 powder
in solvent
别名 BMS-354825

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03625388 Not yet recruiting Chronic Myelogenous Leukemia Hikma Pharmaceuticals LLC October 2018 Phase 2
NCT03516279 Not yet recruiting Chronic Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive|Minimal Residual Disease ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group August 12 2018 Phase 2
NCT03595917 Recruiting B-cell Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL Marlise R. Luskin|Novartis|Dana-Farber Cancer Institute July 24 2018 Phase 1
NCT03654768 Recruiting Chronic Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive Southwest Oncology Group|National Cancer Institute (NCI) July 20 2018 Phase 2
NCT03560908 Recruiting Relapsed AML|T(8;21)|C-KIT Mutation Institute of Hematology & Blood Diseases Hospital July 1 2018 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • 回答:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • 问题 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • 回答:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

相关Src产品

Tags: 购买Dasatinib | Dasatinib供应商 | 采购Dasatinib | Dasatinib价格 | Dasatinib生产 | 订购Dasatinib | Dasatinib代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID